Aberrant Splicing | CHOP Research Institute
 

Aberrant Splicing

Published on
Dec 29, 2022
These six Cornerstone stories garnered the most engagements from our CHOP Research Twitter, Facebook, and LinkedIn channels.
Published on
Jan 24, 2022
Researchers identified aberrant splicing as a culprit behind treatment resistance in B-ALL.

The Thomas-Tikhonenko Lab has a long-standing interest in the pathobiology of solid and hematopoietic malignancies, in particular lymphomas and leukemias and other cancers driven by MYC overexpression.

Dr. Thomas-Tikhonenko has a long-standing interest in the pathobiology of solid and hematopoietic malignancies, in particular lymphomas and leukemias and other cancers driven by MYC overexpression. Within that research space, his studies focus mainly (but not exclusively) on RNA-based regulatory mechanisms, such as microRNAs and alternative mRNA splicing.

E-mail:
thomastikhonenko [at] chop.edu